Home
Applications
Indications
Business
EpiSwitch
®
Products
EpiSwitch
®
Checkpoint Inhibitor Response Test
EpiSwitch
®
COVID-19 Severity Test
EpiSwitch
®
Explorer Array Kit
EPISWITCH
®
ANALYTICAL PORTAL
EpiSwitch
®
Service
Investors
Investors Overview
Results and Presentations
Share Price Information
Regulatory News
Board & Governance
Key Corporate Documents
AIM Rule 26
Email Alerts
Investor Contacts
News
About Us
History
Board of Directors
Management Team
Scientific Advisory Panel
Values
Careers
Contact Us
oxfordbiodynamics
Final results for year ended 30 September 2021
Press Release
by oxfordbiodynamics
OBD updates on EpiSwitch CST and CiRT tests
Press Release
by oxfordbiodynamics
Circular to Shareholders 26 October 2021
Press Release
by oxfordbiodynamics
OBD raises £3.62 million
Press Release
by oxfordbiodynamics
Change of Registered Office
Press Release
by oxfordbiodynamics
Oxford BioDynamics awarded US FNIH Grant to apply EpiSwitch
®
Immune Health test for improved prediction of patient response to Immune Checkpoint Inhibitor (ICI) cancer therapies
Press Release
by oxfordbiodynamics
Oxford BioDynamics signs lease for new lab and office space at Oxford Business Park, supporting expanded strategy
Press Release
by oxfordbiodynamics
Oxford BioDynamics signs supply and resale agreement with Agilent
®
Technologies, and launches EpiSwitch
®
Explorer Array Kit for R&D use
Press Release
by oxfordbiodynamics
US launch of EpiSwitch® COVID-19 Severity Test
Press Release
by oxfordbiodynamics
EpiSwitch
®
COVID-19 Severity Test biomarker results published
Press release
by oxfordbiodynamics
1
2
3
…
11
Privacy Preference Center
Privacy Preferences
